Author

Vivek Kolapkar

Institution: Lupin Pharmaceuticals (India)

Observed institutions: Indraprastha Apollo Hospitals, Christian Medical College, Vellore, Lupin Pharmaceuticals (India), Saifee Hospital, Bharti Hospital

ORCID: 0000-0002-7915-9967

Observed ORCID: 0000-0002-7915-9967

OpenAlex ID: A5089086416

Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India

2024 · Sanjay Kalra, Saptarshi Bhattacharya, et al. · Cureus · 5

Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India

2023 · Vivek Kolapkar, J.C. Mohan, et al. · Current Cardiology Reviews · 5

Efficacy and Safety of Vildagliptin Sustained-Release and Metformin Sustained-Release Fixed-Dose Combination in Indian Patients With Type 2 Diabetes Mellitus: A Real-World Perspective

2025 · Archana Sarda, Bhavana Sosale, et al. · Cureus · 2

Expert Opinion Review on the Shift from Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Indian Clinical Practice

2026 · J Ezhilan, PC Manoria, et al. · Journal of the Association of Physicians of India

Expert Opinion on Optimising Guideline-Directed Medical Therapy and Expanding the Role of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) for Heart Failure Management in India

2026 · Bijay Prakash Pandey, Saumitra Ray, et al. · Cureus

Works count: 5

Citation count: 12

H-index: 2

I10-index: